Nuvectis Pharma (NVCT) Stock Price, News & Analysis

Company Overview

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders. Lead candidates are being evaluated for inherited conditions characterized by enzyme deficiencies or receptor dysfunction, with the goal of delivering active protein payloads directly to affected cells. In parallel, the company is exploring applications of its delivery technology in areas such as oncology and inflammatory disease, seeking strategic partnerships to advance select programs into later clinical development.

Headquartered in San Diego, California, Nuvectis Pharma operates with a management team drawn from established life-science and pharmaceutical backgrounds. The company maintains research collaborations with academic centers and contract development organizations to accelerate its discovery and development activities. With a focus on rare diseases and high-unmet-need patient populations, Nuvectis is positioning its platform to address therapeutic challenges that extend beyond the reach of conventional biologic and small-molecule approaches.

Key Stats

• Today's Range: $22.01 to $23.02
• 50-Day Range: $18.03 to $25.89
• 52-Week Range: $5.55 to $29.27
• Volume: 107,047 shs
• Average Volume: 190,110 shs
• Market Capitalization: $734.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.25
• Consensus Rating: Moderate Buy

Nuvectis Pharma Stock Analysis - MarketRank™

Nuvectis Pharma scored higher than 79% of companies evaluated by MarketBeat, and ranked 102nd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nuvectis Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Nuvectis Pharma has a consensus price target of $36.25, representing about 61.2% upside from its current price of $22.49.

Amount of Analyst Coverage

Nuvectis Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nuvectis Pharma are expected to decrease in the coming year, from ($1.01) to ($1.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvectis Pharma is -17.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvectis Pharma is -17.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuvectis Pharma has a P/B Ratio of 31.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.42% of the float of Nuvectis Pharma has been sold short.

Short Interest Ratio / Days to Cover

Nuvectis Pharma has a short interest ratio ("days to cover") of 9.33.

Change versus previous month

Short interest in Nuvectis Pharma has recently increased by 19.59%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvectis Pharma does not currently pay a dividend.

Dividend Growth

Nuvectis Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.99

News Sentiment

Nuvectis Pharma has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Nuvectis Pharma this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Nuvectis Pharma in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $1,166,000.00 in company stock, which represents 0.1588% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,166,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

28.55% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/11/2026
• 12th Annual Cantor Fitzgerald Global Healthcare Conference: 9/11/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/14/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NVCT
• CIK: 1875558
• Web: www.nuvectis.com
• Phone: 201-614-3150
• Fax: N/A
• Employees: 8
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Nuvectis Pharma: $36.25
• High Price Target: $40.00
• Low Price Target: $33.00
• Potential Upside/Downside: +61.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -184.25%
• Return on Assets: -105.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.68
• Quick Ratio: 1.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 31.24

Miscellaneous

• Outstanding Shares: 32,640,000
• Free Float: 23,324,000
• Market Cap: $734.07 million
• Optionable: Not Optionable
• Beta: -0.26